Here we demonstrate SDF exhibit an enhanced cell surface expression of the TGF-1 accessory receptor TGFRIII (betaglycan), but not type I (ALK1 and ALK5) or
Structure-Based Design of mTORC1 Inhibitors in Cancer Therapy
mTORC1 inhibitor
mTORC1 inhibitor
Here we demonstrate SDF exhibit an enhanced cell surface expression of the TGF-1 accessory receptor TGFRIII (betaglycan), but not type I (ALK1 and ALK5) or